Terms: = Sarcomas AND FOXO1, Q12778, FOXO1A, 2308, ENSG00000150907, FKH1, FKHR AND Clinical Outcome
11 results:
1. PAX-foxo1 fusion status in children and adolescents with alveolar rhabdomyosarcoma: Impact on clinical, pathological, and survival features.
Raze T; Lapouble E; Lacour B; Guissou S; Defachelles AS; Gaspar N; Delattre O; Pierron G; Desandes E
Pediatr Blood Cancer; 2023 Apr; 70(4):e30228. PubMed ID: 36722003
[TBL] [Abstract] [Full Text] [Related]
2. Improving Risk Stratification for Pediatric Patients with Rhabdomyosarcoma by Molecular Detection of Disseminated Disease.
Lak NSM; Voormanns TL; Zappeij-Kannegieter L; van Zogchel LMJ; Fiocco M; van Noesel MM; Merks JHM; van der Schoot CE; Tytgat GAM; Stutterheim J
Clin Cancer Res; 2021 Oct; 27(20):5576-5585. PubMed ID: 34285060
[TBL] [Abstract] [Full Text] [Related]
3. Genomic Classification and clinical outcome in Rhabdomyosarcoma: A Report From an International Consortium.
Shern JF; Selfe J; Izquierdo E; Patidar R; Chou HC; Song YK; Yohe ME; Sindiri S; Wei J; Wen X; Rudzinski ER; Barkauskas DA; Lo T; Hall D; Linardic CM; Hughes D; Jamal S; Jenney M; Chisholm J; Brown R; Jones K; Hicks B; Angelini P; George S; Chesler L; Hubank M; Kelsey A; Gatz SA; Skapek SX; Hawkins DS; Shipley JM; Khan J
J Clin Oncol; 2021 Sep; 39(26):2859-2871. PubMed ID: 34166060
[TBL] [Abstract] [Full Text] [Related]
4. Refinement of risk stratification for childhood rhabdomyosarcoma using foxo1 fusion status in addition to established clinical outcome predictors: A report from the Children's Oncology Group.
Hibbitts E; Chi YY; Hawkins DS; Barr FG; Bradley JA; Dasgupta R; Meyer WH; Rodeberg DA; Rudzinski ER; Spunt SL; Skapek SX; Wolden SL; Arndt CAS
Cancer Med; 2019 Oct; 8(14):6437-6448. PubMed ID: 31456361
[TBL] [Abstract] [Full Text] [Related]
5. clinical and Cytogenetic Profiles of Rhabdomyosarcoma with Bone Marrow Involvement in Korean Children: A 15-Year Single-Institution Experience.
Lee DH; Park CJ; Jang S; Cho YU; Seo JJ; Im HJ; Koh KN; Cho KJ; Song JS; Seo EJ
Ann Lab Med; 2018 Mar; 38(2):132-138. PubMed ID: 29214757
[TBL] [Abstract] [Full Text] [Related]
6. MicroRNA and gene co-expression networks characterize biological and clinical behavior of rhabdomyosarcomas.
Missiaglia E; Shepherd CJ; Aladowicz E; Olmos D; Selfe J; Pierron G; Delattre O; Walters Z; Shipley J
Cancer Lett; 2017 Jan; 385():251-260. PubMed ID: 27984116
[TBL] [Abstract] [Full Text] [Related]
7. PAX7 is a required target for microRNA-206-induced differentiation of fusion-negative rhabdomyosarcoma.
Hanna JA; Garcia MR; Go JC; Finkelstein D; Kodali K; Pagala V; Wang X; Peng J; Hatley ME
Cell Death Dis; 2016 Jun; 7(6):e2256. PubMed ID: 27277678
[TBL] [Abstract] [Full Text] [Related]
8. Genomic and clinical analyses of 2p24 and 12q13-q14 amplification in alveolar rhabdomyosarcoma: a report from the Children's Oncology Group.
Barr FG; Duan F; Smith LM; Gustafson D; Pitts M; Hammond S; Gastier-Foster JM
Genes Chromosomes Cancer; 2009 Aug; 48(8):661-72. PubMed ID: 19422036
[TBL] [Abstract] [Full Text] [Related]
9. Rhabdomyosarcoma: molecular diagnostics of patients classified by morphology and immunohistochemistry with emphasis on bone marrow and purged peripheral blood progenitor cells involvement.
Krsková L; Mrhalová M; Sumerauer D; Kodet R
Virchows Arch; 2006 Apr; 448(4):449-58. PubMed ID: 16365729
[TBL] [Abstract] [Full Text] [Related]
10. Cytogenetic and molecular findings related to rhabdomyosarcoma. An analysis of seven cases.
Gil-Benso R; López-Ginés C; Carda C; López-Guerrero JA; Ferrer J; Pellín-Pérez A; Llombart-Bosch A
Cancer Genet Cytogenet; 2003 Jul; 144(2):125-33. PubMed ID: 12850375
[TBL] [Abstract] [Full Text] [Related]
11. PAX3-fkhr and PAX7-fkhr gene fusions are prognostic indicators in alveolar rhabdomyosarcoma: a report from the children's oncology group.
Sorensen PH; Lynch JC; Qualman SJ; Tirabosco R; Lim JF; Maurer HM; Bridge JA; Crist WM; Triche TJ; Barr FG
J Clin Oncol; 2002 Jun; 20(11):2672-9. PubMed ID: 12039929
[TBL] [Abstract] [Full Text] [Related]
